top of page

USFDA Guidance: Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions

Writer's picture: Sharan MuruganSharan Murugan

Yesterday (08 January, 2024) the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research Center for Devices and Radiological Health released the final guidance "Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile".


In this guideline, the scope of review is limited to 510(k)s for devices labeled as sterile, which undergo industrial terminal sterilization processes based on microbial inactivation. Examples of these processes include radiation, steam, EO, and new technology sterilization processes.


This guidance updates and clarifies the information regarding sterilization processes that we recommend sponsors include in 510(k)s for devices labeled as sterile, also discusses what information sponsors should include when submitting a 510(k) concerning pyrogenicity.


FDA considers there to be two categories of sterilization methods currently used to sterilize medical devices in manufacturing settings:

A. Established Sterilization Methods

  • Established Category A: For established methods such as dry heat, EO, steam, radiation, and vaporized hydrogen peroxide, there are voluntary consensus standards for development, validation, and routine control that are recognized by FDA.

  • Established Category B: In cases where FDA has previously evaluated sterilization development and validation data for specific sterilizers using discrete cycle parameters and determined the validation methods to be adequate, it is considered as Established Category B.

B. Novel Sterilization Methods: A Novel Sterilization Method is a method that FDA has not reviewed and determined to be adequate to effectively sterilize the device for its intended use.


To understand the requirements and to see more examples click this LINK.


Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page